Varenicline Tartrate

酒石酸伐尼克兰

Report date: 2026/04/03 20:03:44
NMEFirst In Class

Base Information

Drug NameVarenicline Tartrate
Drug Alias Name酒石酸瓦伦尼林vareniclinum酒石酸瓦伦尼克林伐仑克林酒石酸盐酒石酸伐伦克林 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNicotinic acetylcholine receptor alpha-4/beta-2 agonists
TargetsNicotinic acetylcholine receptor alpha-4/beta-2
Therapy Area/IndicationsStress Disorders, Post-TraumaticSchizophreniaCognition +[35] 
Global Approved IndicationsTobacco Use CessationSmoking CessationTobacco Use Disorder
Approved Indications in ChinaTobacco Use Disorder
Original Approved Country/TerritoryUnited States
Original Approved Date2006/05/10
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTSH Biopharm Corp LtdYale UniversityPfizer Inc +[13] 
Inactive CompaniesVancouver Coastal Health Research InstituteUniversity Of California San FranciscoNational Institutes Of Health +[32] 
Active IndicationsTobacco UseVapingCigarette Smoking +[14] 
Inactive IndicationsStress Disorders, Post-TraumaticSchizophreniaCognition +[21] 

Other Information

ATC CodeN07BA03
Related LinksWikipediaDrugBankKEGG